T.O. Kong

Wilson Sonsini Goodrich & Rosati

+ Follow Contact

Latest Posts › Life Sciences

Share:

The Life Sciences Report – June 2025

This latest edition features articles on succeeding in the current life sciences funding market, strategic and legal considerations in digital health combinations, the corporate practice of medicine and guidance for...more

6/4/2025 / Digital Health , Healthcare , Intellectual Property Protection , Investment , Life Sciences , Patents , Pharmaceutical Industry , Regulatory Requirements , Venture Capital

The Life Sciences Report – January 2025

This latest edition features an interview with retiring longtime Wilson Sonsini IP partner Vern Norviel and articles on MedTech and pharma trends for 2025, the eligibility of life sciences companies for qualified small...more

1/9/2025 / Brand , Initial Public Offering (IPO) , Intellectual Property Protection , Life Sciences , Medical Devices , Patents , Pharmaceutical Industry , Regulatory Reform , Venture Capital

Federal Circuit Affirms Jazz Pharmaceutical's Risk Evaluation and Mitigation Strategy Patent Is Not Listable in Orange Book

On February 24, 2023, the Federal Circuit held that Jazz Pharmaceuticals, Inc. (Jazz) must delist U.S. Patent No. 8,731,963 (the ’963 Patent) from the U.S. Food and Drug Administration’s (FDA’s) “Orange Book” because the...more

3/14/2023 / FDA Approval , Food and Drug Administration (FDA) , Life Sciences , Patent Litigation , Patents , Pharmaceutical Industry , Pharmaceutical Patents , Prescription Drugs

3 Results

View per page

Page: of 1